Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block
In the first part a prospective cohort study was reported to evaluate the efficacy and safety of a treatment protocol including plasma exchange (PE) or PE plus intravenous immunoglobulins (IVIG) or immunoadsorption (IA) plus IVIG administered in addition to conventional therapy to 22 pregnant women...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Ruffatti, Amelia [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2015transfer abstract |
|---|
| Umfang: |
10 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease - Lopategi, A. ELSEVIER, 2016, official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, Oxford |
|---|---|
| Übergeordnetes Werk: |
volume:53 ; year:2015 ; number:3 ; pages:269-278 ; extent:10 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.transci.2015.11.006 |
|---|
| Katalog-ID: |
ELV028710223 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV028710223 | ||
| 003 | DE-627 | ||
| 005 | 20230625162443.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.transci.2015.11.006 |2 doi | |
| 028 | 5 | 2 | |a GBVA2015004000029.pica |
| 035 | |a (DE-627)ELV028710223 | ||
| 035 | |a (ELSEVIER)S1473-0502(15)00185-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.44 |2 bkl | ||
| 100 | 1 | |a Ruffatti, Amelia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block |
| 264 | 1 | |c 2015transfer abstract | |
| 300 | |a 10 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a In the first part a prospective cohort study was reported to evaluate the efficacy and safety of a treatment protocol including plasma exchange (PE) or PE plus intravenous immunoglobulins (IVIG) or immunoadsorption (IA) plus IVIG administered in addition to conventional therapy to 22 pregnant women with high-risk APS. The results indicate that PE or IA treatments administered along with IVIG and conventional antithrombotic therapy could be a valuable and safe therapeutic option in pregnant APS women with triple antiphospholipid antibody positivity along with a history of thrombosis and/or one or more severe pregnancy complications. | ||
| 520 | |a In the first part a prospective cohort study was reported to evaluate the efficacy and safety of a treatment protocol including plasma exchange (PE) or PE plus intravenous immunoglobulins (IVIG) or immunoadsorption (IA) plus IVIG administered in addition to conventional therapy to 22 pregnant women with high-risk APS. The results indicate that PE or IA treatments administered along with IVIG and conventional antithrombotic therapy could be a valuable and safe therapeutic option in pregnant APS women with triple antiphospholipid antibody positivity along with a history of thrombosis and/or one or more severe pregnancy complications. | ||
| 700 | 1 | |a Favaro, Maria |4 oth | |
| 700 | 1 | |a Brucato, Antonio |4 oth | |
| 700 | 1 | |a Ramoni, Veronique |4 oth | |
| 700 | 1 | |a Facchinetti, Myriam |4 oth | |
| 700 | 1 | |a Tonello, Marta |4 oth | |
| 700 | 1 | |a Del Ross, Teresa |4 oth | |
| 700 | 1 | |a Calligaro, Antonia |4 oth | |
| 700 | 1 | |a Hoxha, Ariela |4 oth | |
| 700 | 1 | |a Grava, Chiara |4 oth | |
| 700 | 1 | |a De Silvestro, Giustina |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier [u.a.] |a Lopategi, A. ELSEVIER |t Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease |d 2016 |d official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis |g Oxford |w (DE-627)ELV01380703X |
| 773 | 1 | 8 | |g volume:53 |g year:2015 |g number:3 |g pages:269-278 |g extent:10 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.transci.2015.11.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_26 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_252 | ||
| 936 | b | k | |a 44.44 |j Parasitologie |x Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 53 |j 2015 |e 3 |h 269-278 |g 10 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
a r ar |
|---|---|
| matchkey_str |
ruffattiameliafavaromariabrucatoantonior:2015----:peeiihgrsatpopoiisnrmpennynatim |
| hierarchy_sort_str |
2015transfer abstract |
| bklnumber |
44.44 |
| publishDate |
2015 |
| allfields |
10.1016/j.transci.2015.11.006 doi GBVA2015004000029.pica (DE-627)ELV028710223 (ELSEVIER)S1473-0502(15)00185-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.44 bkl Ruffatti, Amelia verfasserin aut Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block 2015transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In the first part a prospective cohort study was reported to evaluate the efficacy and safety of a treatment protocol including plasma exchange (PE) or PE plus intravenous immunoglobulins (IVIG) or immunoadsorption (IA) plus IVIG administered in addition to conventional therapy to 22 pregnant women with high-risk APS. The results indicate that PE or IA treatments administered along with IVIG and conventional antithrombotic therapy could be a valuable and safe therapeutic option in pregnant APS women with triple antiphospholipid antibody positivity along with a history of thrombosis and/or one or more severe pregnancy complications. In the first part a prospective cohort study was reported to evaluate the efficacy and safety of a treatment protocol including plasma exchange (PE) or PE plus intravenous immunoglobulins (IVIG) or immunoadsorption (IA) plus IVIG administered in addition to conventional therapy to 22 pregnant women with high-risk APS. The results indicate that PE or IA treatments administered along with IVIG and conventional antithrombotic therapy could be a valuable and safe therapeutic option in pregnant APS women with triple antiphospholipid antibody positivity along with a history of thrombosis and/or one or more severe pregnancy complications. Favaro, Maria oth Brucato, Antonio oth Ramoni, Veronique oth Facchinetti, Myriam oth Tonello, Marta oth Del Ross, Teresa oth Calligaro, Antonia oth Hoxha, Ariela oth Grava, Chiara oth De Silvestro, Giustina oth Enthalten in Elsevier [u.a.] Lopategi, A. ELSEVIER Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease 2016 official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis Oxford (DE-627)ELV01380703X volume:53 year:2015 number:3 pages:269-278 extent:10 https://doi.org/10.1016/j.transci.2015.11.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_26 GBV_ILN_40 GBV_ILN_252 44.44 Parasitologie Medizin VZ AR 53 2015 3 269-278 10 045F 610 |
| spelling |
10.1016/j.transci.2015.11.006 doi GBVA2015004000029.pica (DE-627)ELV028710223 (ELSEVIER)S1473-0502(15)00185-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.44 bkl Ruffatti, Amelia verfasserin aut Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block 2015transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In the first part a prospective cohort study was reported to evaluate the efficacy and safety of a treatment protocol including plasma exchange (PE) or PE plus intravenous immunoglobulins (IVIG) or immunoadsorption (IA) plus IVIG administered in addition to conventional therapy to 22 pregnant women with high-risk APS. The results indicate that PE or IA treatments administered along with IVIG and conventional antithrombotic therapy could be a valuable and safe therapeutic option in pregnant APS women with triple antiphospholipid antibody positivity along with a history of thrombosis and/or one or more severe pregnancy complications. In the first part a prospective cohort study was reported to evaluate the efficacy and safety of a treatment protocol including plasma exchange (PE) or PE plus intravenous immunoglobulins (IVIG) or immunoadsorption (IA) plus IVIG administered in addition to conventional therapy to 22 pregnant women with high-risk APS. The results indicate that PE or IA treatments administered along with IVIG and conventional antithrombotic therapy could be a valuable and safe therapeutic option in pregnant APS women with triple antiphospholipid antibody positivity along with a history of thrombosis and/or one or more severe pregnancy complications. Favaro, Maria oth Brucato, Antonio oth Ramoni, Veronique oth Facchinetti, Myriam oth Tonello, Marta oth Del Ross, Teresa oth Calligaro, Antonia oth Hoxha, Ariela oth Grava, Chiara oth De Silvestro, Giustina oth Enthalten in Elsevier [u.a.] Lopategi, A. ELSEVIER Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease 2016 official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis Oxford (DE-627)ELV01380703X volume:53 year:2015 number:3 pages:269-278 extent:10 https://doi.org/10.1016/j.transci.2015.11.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_26 GBV_ILN_40 GBV_ILN_252 44.44 Parasitologie Medizin VZ AR 53 2015 3 269-278 10 045F 610 |
| allfields_unstemmed |
10.1016/j.transci.2015.11.006 doi GBVA2015004000029.pica (DE-627)ELV028710223 (ELSEVIER)S1473-0502(15)00185-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.44 bkl Ruffatti, Amelia verfasserin aut Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block 2015transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In the first part a prospective cohort study was reported to evaluate the efficacy and safety of a treatment protocol including plasma exchange (PE) or PE plus intravenous immunoglobulins (IVIG) or immunoadsorption (IA) plus IVIG administered in addition to conventional therapy to 22 pregnant women with high-risk APS. The results indicate that PE or IA treatments administered along with IVIG and conventional antithrombotic therapy could be a valuable and safe therapeutic option in pregnant APS women with triple antiphospholipid antibody positivity along with a history of thrombosis and/or one or more severe pregnancy complications. In the first part a prospective cohort study was reported to evaluate the efficacy and safety of a treatment protocol including plasma exchange (PE) or PE plus intravenous immunoglobulins (IVIG) or immunoadsorption (IA) plus IVIG administered in addition to conventional therapy to 22 pregnant women with high-risk APS. The results indicate that PE or IA treatments administered along with IVIG and conventional antithrombotic therapy could be a valuable and safe therapeutic option in pregnant APS women with triple antiphospholipid antibody positivity along with a history of thrombosis and/or one or more severe pregnancy complications. Favaro, Maria oth Brucato, Antonio oth Ramoni, Veronique oth Facchinetti, Myriam oth Tonello, Marta oth Del Ross, Teresa oth Calligaro, Antonia oth Hoxha, Ariela oth Grava, Chiara oth De Silvestro, Giustina oth Enthalten in Elsevier [u.a.] Lopategi, A. ELSEVIER Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease 2016 official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis Oxford (DE-627)ELV01380703X volume:53 year:2015 number:3 pages:269-278 extent:10 https://doi.org/10.1016/j.transci.2015.11.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_26 GBV_ILN_40 GBV_ILN_252 44.44 Parasitologie Medizin VZ AR 53 2015 3 269-278 10 045F 610 |
| allfieldsGer |
10.1016/j.transci.2015.11.006 doi GBVA2015004000029.pica (DE-627)ELV028710223 (ELSEVIER)S1473-0502(15)00185-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.44 bkl Ruffatti, Amelia verfasserin aut Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block 2015transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In the first part a prospective cohort study was reported to evaluate the efficacy and safety of a treatment protocol including plasma exchange (PE) or PE plus intravenous immunoglobulins (IVIG) or immunoadsorption (IA) plus IVIG administered in addition to conventional therapy to 22 pregnant women with high-risk APS. The results indicate that PE or IA treatments administered along with IVIG and conventional antithrombotic therapy could be a valuable and safe therapeutic option in pregnant APS women with triple antiphospholipid antibody positivity along with a history of thrombosis and/or one or more severe pregnancy complications. In the first part a prospective cohort study was reported to evaluate the efficacy and safety of a treatment protocol including plasma exchange (PE) or PE plus intravenous immunoglobulins (IVIG) or immunoadsorption (IA) plus IVIG administered in addition to conventional therapy to 22 pregnant women with high-risk APS. The results indicate that PE or IA treatments administered along with IVIG and conventional antithrombotic therapy could be a valuable and safe therapeutic option in pregnant APS women with triple antiphospholipid antibody positivity along with a history of thrombosis and/or one or more severe pregnancy complications. Favaro, Maria oth Brucato, Antonio oth Ramoni, Veronique oth Facchinetti, Myriam oth Tonello, Marta oth Del Ross, Teresa oth Calligaro, Antonia oth Hoxha, Ariela oth Grava, Chiara oth De Silvestro, Giustina oth Enthalten in Elsevier [u.a.] Lopategi, A. ELSEVIER Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease 2016 official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis Oxford (DE-627)ELV01380703X volume:53 year:2015 number:3 pages:269-278 extent:10 https://doi.org/10.1016/j.transci.2015.11.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_26 GBV_ILN_40 GBV_ILN_252 44.44 Parasitologie Medizin VZ AR 53 2015 3 269-278 10 045F 610 |
| allfieldsSound |
10.1016/j.transci.2015.11.006 doi GBVA2015004000029.pica (DE-627)ELV028710223 (ELSEVIER)S1473-0502(15)00185-8 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.44 bkl Ruffatti, Amelia verfasserin aut Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block 2015transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In the first part a prospective cohort study was reported to evaluate the efficacy and safety of a treatment protocol including plasma exchange (PE) or PE plus intravenous immunoglobulins (IVIG) or immunoadsorption (IA) plus IVIG administered in addition to conventional therapy to 22 pregnant women with high-risk APS. The results indicate that PE or IA treatments administered along with IVIG and conventional antithrombotic therapy could be a valuable and safe therapeutic option in pregnant APS women with triple antiphospholipid antibody positivity along with a history of thrombosis and/or one or more severe pregnancy complications. In the first part a prospective cohort study was reported to evaluate the efficacy and safety of a treatment protocol including plasma exchange (PE) or PE plus intravenous immunoglobulins (IVIG) or immunoadsorption (IA) plus IVIG administered in addition to conventional therapy to 22 pregnant women with high-risk APS. The results indicate that PE or IA treatments administered along with IVIG and conventional antithrombotic therapy could be a valuable and safe therapeutic option in pregnant APS women with triple antiphospholipid antibody positivity along with a history of thrombosis and/or one or more severe pregnancy complications. Favaro, Maria oth Brucato, Antonio oth Ramoni, Veronique oth Facchinetti, Myriam oth Tonello, Marta oth Del Ross, Teresa oth Calligaro, Antonia oth Hoxha, Ariela oth Grava, Chiara oth De Silvestro, Giustina oth Enthalten in Elsevier [u.a.] Lopategi, A. ELSEVIER Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease 2016 official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis Oxford (DE-627)ELV01380703X volume:53 year:2015 number:3 pages:269-278 extent:10 https://doi.org/10.1016/j.transci.2015.11.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_26 GBV_ILN_40 GBV_ILN_252 44.44 Parasitologie Medizin VZ AR 53 2015 3 269-278 10 045F 610 |
| language |
English |
| source |
Enthalten in Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease Oxford volume:53 year:2015 number:3 pages:269-278 extent:10 |
| sourceStr |
Enthalten in Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease Oxford volume:53 year:2015 number:3 pages:269-278 extent:10 |
| format_phy_str_mv |
Article |
| bklname |
Parasitologie |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease |
| authorswithroles_txt_mv |
Ruffatti, Amelia @@aut@@ Favaro, Maria @@oth@@ Brucato, Antonio @@oth@@ Ramoni, Veronique @@oth@@ Facchinetti, Myriam @@oth@@ Tonello, Marta @@oth@@ Del Ross, Teresa @@oth@@ Calligaro, Antonia @@oth@@ Hoxha, Ariela @@oth@@ Grava, Chiara @@oth@@ De Silvestro, Giustina @@oth@@ |
| publishDateDaySort_date |
2015-01-01T00:00:00Z |
| hierarchy_top_id |
ELV01380703X |
| dewey-sort |
3610 |
| id |
ELV028710223 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV028710223</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625162443.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.transci.2015.11.006</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015004000029.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV028710223</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1473-0502(15)00185-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.44</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ruffatti, Amelia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In the first part a prospective cohort study was reported to evaluate the efficacy and safety of a treatment protocol including plasma exchange (PE) or PE plus intravenous immunoglobulins (IVIG) or immunoadsorption (IA) plus IVIG administered in addition to conventional therapy to 22 pregnant women with high-risk APS. The results indicate that PE or IA treatments administered along with IVIG and conventional antithrombotic therapy could be a valuable and safe therapeutic option in pregnant APS women with triple antiphospholipid antibody positivity along with a history of thrombosis and/or one or more severe pregnancy complications.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In the first part a prospective cohort study was reported to evaluate the efficacy and safety of a treatment protocol including plasma exchange (PE) or PE plus intravenous immunoglobulins (IVIG) or immunoadsorption (IA) plus IVIG administered in addition to conventional therapy to 22 pregnant women with high-risk APS. The results indicate that PE or IA treatments administered along with IVIG and conventional antithrombotic therapy could be a valuable and safe therapeutic option in pregnant APS women with triple antiphospholipid antibody positivity along with a history of thrombosis and/or one or more severe pregnancy complications.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Favaro, Maria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brucato, Antonio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ramoni, Veronique</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Facchinetti, Myriam</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tonello, Marta</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Del Ross, Teresa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Calligaro, Antonia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hoxha, Ariela</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grava, Chiara</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">De Silvestro, Giustina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier [u.a.]</subfield><subfield code="a">Lopategi, A. ELSEVIER</subfield><subfield code="t">Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease</subfield><subfield code="d">2016</subfield><subfield code="d">official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis</subfield><subfield code="g">Oxford</subfield><subfield code="w">(DE-627)ELV01380703X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:53</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:269-278</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.transci.2015.11.006</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_26</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_252</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.44</subfield><subfield code="j">Parasitologie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">53</subfield><subfield code="j">2015</subfield><subfield code="e">3</subfield><subfield code="h">269-278</subfield><subfield code="g">10</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Ruffatti, Amelia |
| spellingShingle |
Ruffatti, Amelia ddc 610 bkl 44.44 Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block |
| authorStr |
Ruffatti, Amelia |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV01380703X |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 44.44 bkl Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block |
| topic |
ddc 610 bkl 44.44 |
| topic_unstemmed |
ddc 610 bkl 44.44 |
| topic_browse |
ddc 610 bkl 44.44 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m f mf a b ab v r vr m f mf m t mt r t d rt rtd a c ac a h ah c g cg s g d sg sgd |
| hierarchy_parent_title |
Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease |
| hierarchy_parent_id |
ELV01380703X |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV01380703X |
| title |
Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block |
| ctrlnum |
(DE-627)ELV028710223 (ELSEVIER)S1473-0502(15)00185-8 |
| title_full |
Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block |
| author_sort |
Ruffatti, Amelia |
| journal |
Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease |
| journalStr |
Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2015 |
| contenttype_str_mv |
zzz |
| container_start_page |
269 |
| author_browse |
Ruffatti, Amelia |
| container_volume |
53 |
| physical |
10 |
| class |
610 610 DE-600 610 VZ 44.44 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Ruffatti, Amelia |
| doi_str_mv |
10.1016/j.transci.2015.11.006 |
| dewey-full |
610 |
| title_sort |
apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block |
| title_auth |
Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block |
| abstract |
In the first part a prospective cohort study was reported to evaluate the efficacy and safety of a treatment protocol including plasma exchange (PE) or PE plus intravenous immunoglobulins (IVIG) or immunoadsorption (IA) plus IVIG administered in addition to conventional therapy to 22 pregnant women with high-risk APS. The results indicate that PE or IA treatments administered along with IVIG and conventional antithrombotic therapy could be a valuable and safe therapeutic option in pregnant APS women with triple antiphospholipid antibody positivity along with a history of thrombosis and/or one or more severe pregnancy complications. |
| abstractGer |
In the first part a prospective cohort study was reported to evaluate the efficacy and safety of a treatment protocol including plasma exchange (PE) or PE plus intravenous immunoglobulins (IVIG) or immunoadsorption (IA) plus IVIG administered in addition to conventional therapy to 22 pregnant women with high-risk APS. The results indicate that PE or IA treatments administered along with IVIG and conventional antithrombotic therapy could be a valuable and safe therapeutic option in pregnant APS women with triple antiphospholipid antibody positivity along with a history of thrombosis and/or one or more severe pregnancy complications. |
| abstract_unstemmed |
In the first part a prospective cohort study was reported to evaluate the efficacy and safety of a treatment protocol including plasma exchange (PE) or PE plus intravenous immunoglobulins (IVIG) or immunoadsorption (IA) plus IVIG administered in addition to conventional therapy to 22 pregnant women with high-risk APS. The results indicate that PE or IA treatments administered along with IVIG and conventional antithrombotic therapy could be a valuable and safe therapeutic option in pregnant APS women with triple antiphospholipid antibody positivity along with a history of thrombosis and/or one or more severe pregnancy complications. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_26 GBV_ILN_40 GBV_ILN_252 |
| container_issue |
3 |
| title_short |
Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block |
| url |
https://doi.org/10.1016/j.transci.2015.11.006 |
| remote_bool |
true |
| author2 |
Favaro, Maria Brucato, Antonio Ramoni, Veronique Facchinetti, Myriam Tonello, Marta Del Ross, Teresa Calligaro, Antonia Hoxha, Ariela Grava, Chiara De Silvestro, Giustina |
| author2Str |
Favaro, Maria Brucato, Antonio Ramoni, Veronique Facchinetti, Myriam Tonello, Marta Del Ross, Teresa Calligaro, Antonia Hoxha, Ariela Grava, Chiara De Silvestro, Giustina |
| ppnlink |
ELV01380703X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.transci.2015.11.006 |
| up_date |
2024-07-06T19:31:50.223Z |
| _version_ |
1803859326638489600 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV028710223</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625162443.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.transci.2015.11.006</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015004000029.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV028710223</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1473-0502(15)00185-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.44</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ruffatti, Amelia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Apheresis in high risk antiphospholipid syndrome pregnancy and autoimmune congenital heart block</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In the first part a prospective cohort study was reported to evaluate the efficacy and safety of a treatment protocol including plasma exchange (PE) or PE plus intravenous immunoglobulins (IVIG) or immunoadsorption (IA) plus IVIG administered in addition to conventional therapy to 22 pregnant women with high-risk APS. The results indicate that PE or IA treatments administered along with IVIG and conventional antithrombotic therapy could be a valuable and safe therapeutic option in pregnant APS women with triple antiphospholipid antibody positivity along with a history of thrombosis and/or one or more severe pregnancy complications.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In the first part a prospective cohort study was reported to evaluate the efficacy and safety of a treatment protocol including plasma exchange (PE) or PE plus intravenous immunoglobulins (IVIG) or immunoadsorption (IA) plus IVIG administered in addition to conventional therapy to 22 pregnant women with high-risk APS. The results indicate that PE or IA treatments administered along with IVIG and conventional antithrombotic therapy could be a valuable and safe therapeutic option in pregnant APS women with triple antiphospholipid antibody positivity along with a history of thrombosis and/or one or more severe pregnancy complications.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Favaro, Maria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brucato, Antonio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ramoni, Veronique</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Facchinetti, Myriam</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tonello, Marta</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Del Ross, Teresa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Calligaro, Antonia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hoxha, Ariela</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grava, Chiara</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">De Silvestro, Giustina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier [u.a.]</subfield><subfield code="a">Lopategi, A. ELSEVIER</subfield><subfield code="t">Pro-Resolving Lipid Mediators Modulate the NLRP3 Inflammasome in Chronic Liver Disease</subfield><subfield code="d">2016</subfield><subfield code="d">official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis</subfield><subfield code="g">Oxford</subfield><subfield code="w">(DE-627)ELV01380703X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:53</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:269-278</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.transci.2015.11.006</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_26</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_252</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.44</subfield><subfield code="j">Parasitologie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">53</subfield><subfield code="j">2015</subfield><subfield code="e">3</subfield><subfield code="h">269-278</subfield><subfield code="g">10</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4024982 |